New financing round for dry eye portfolio


Novaliq has secured €13.9 million in a fifth round of financing for a dry eye portfolio.

Novaliq has secured €13.9 million in a fifth round of financing for a dry eye portfolio.

Exclusive financing was obtained from Dievini Hopp, an active investor in life and health sciences. The funds will be used to progress the pharmaceutical project CyclASol into clinical development. Since 2007 the firm has raised €27.1 million for the dry eye treatment portfolio.

Dievini Hopp Managing Director, Mathias Hothum, stated, "Novaliq is an entirely new class of topical drugs for ophthalmic indications, including dry eye, which have the capability to offer compelling alternatives to current products. We are delighted to invest further in Novaliq, with its pioneering ocular drug delivery technology and strong management team."

Bernhard Günther, CEO of Novaliq, commented, "We are pleased about the ongoing confidence and support from our investor in order to systematically develop the company with our technology platform. Our leading prescription product, CyclASol, is the first Cyclosporine A solution for dry eye disease, while other products are based on emulsions, containing potentially irritating surfactants."

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.